Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence. Issue 5 (25th October 2013)

• Record Type: Journal Article
• Authors: Tanou, Kalliopi; Zintzaras, Elias; Kaditis, Athanasios G.
• Is Part Of: Pediatric pulmonology. Volume 49:Issue 5(2014:May)
• Page Start: 503
• Page End: 507
• Publication Date: 2013-10-25
• Subjects: Pediatric respiratory diseases -- Periodicals; Pediatrics -- Periodicals; 618.922
• DOI: 10.1002/ppul.22937
• Languages: English
• ISSNs: 8755-6863

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Summary</title> <sec id="ppul22937-sec-0001" sec-type="section"> <p>Allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis (CF) is treated with corticosteroids. Since elevated IgE is a cardinal abnormality, anti‐IgE has been used sporadically as adjuvant treatment. In eight case reports, 13 children with CF and ABPA received anti‐IgE resulting in improved FEV₁, fewer respiratory symptoms and decreased corticosteroid use. <bold>Pediatr Pulmonol. 2014; 49:503–507.</bold> © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>